Acadia Battles Back With Latest Nuplazid Data As Trial Is Stopped Early On Successful FindingSeeking Alpha • 09/13/19
'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia PsychosisBenzinga • 09/10/19
Acadia Stops Nuplazid Study Early After Drug Shows 'Statistically Superior Efficacy' In Dementia-Related PsychosisBenzinga • 09/09/19
Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpointMarket Watch • 09/09/19
ACADIA Pharmaceuticals Inc. (ACAD) Shares March Higher, Can It Continue?Zacks Investment Research • 08/06/19
ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/01/19
Acadia May Have Lost The Battle In Its Phase 3 Study, But A Path Forward RemainsSeeking Alpha • 07/31/19